RxDoctor Payments Data

Gisell Mansur, MD

Internal Medicine · Coral Gables, FLNPI 1053833137

Payments from drug & device makers

$2,587in general payments, 2019–2025

Across 115 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$460
  • Novartis$363
  • Johnson & Johnson$290
  • Novo Nordisk$184
  • Exact Sciences$180
  • Lilly USA, LLC$166
  • plus $945 from 17 others

What the payments were for

  • Food & beverage$2,576100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,587 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$25,444
Medicare patients
74
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$44,506
OzempicSemaglutide31$38,951
EliquisApixaban18$21,210
RybelsusSemaglutide15$17,662
EntrestoSacubitril/Valsartan11$7,369
SynthroidLevothyroxine Sodium12$1,590
Rosuvastatin Calcium64$1,015
Atorvastatin Calcium72$506
Diclofenac Sodium20$465
Fluoxetine Hcl15$387
Esomeprazole Magnesium11$360
Tamsulosin Hcl20$340
Fluticasone Propionate33$337
Omeprazole28$328
Metoprolol Succinate33$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$184$56,61346 claims
Boehringer IngelheimJardiance$21$44,50639 claims
PfizerEliquis$44$21,21018 claims
NovartisEntresto$363$7,36911 claims
AbbVieSynthroid$460$1,59012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →